Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
EditorialEditorial

Accelerated Atherosclerosis in Rheumatoid Arthritis: Rationale for Mannose-binding Lectins?

BRITT NAKKEN and PETER SZODORAY
The Journal of Rheumatology March 2010, 37 (3) 482-484; DOI: https://doi.org/10.3899/jrheum.091364
BRITT NAKKEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PETER SZODORAY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: szodoray@gmail.com
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Rheumatoid arthritis (RA) is characterized by chronic inflammation involving connective tissues throughout the body, particularly diarthrodial joints, eventually leading to joint destruction and physical disability1. In parallel with erosive arthritis, other extraarticular manifestations have been described in the disease, representing systemic activation of the immune system1, which is generally associated with excess mortality2. Atherosclerosis, among others, is considered an extraarticular manifestation of RA3. Well established RA reduces median life expectancy, compared to that of healthy subjects4,5. Overall, about 40% excess mortality has been shown in RA6. In addition to infections and gastrointestinal hemorrhage due to nonsteroidal antiinflammatory drugs (NSAID), cardiovascular (CV) mortality is increased in RA. Besides CV diseases, the leading causes of death in RA are infection and malignancies, which also contribute to increased mortality7,8.

Accelerated atherosclerosis in RA is signified by increased CV morbidity and mortality8–12. Generally, in patients with RA, CV diseases reduce life expectancy by 5 to 10 years on average13–15. In both RA and atherosclerosis, inflammatory immune-mediated processes play central roles, and the 2 diseases share several common pathogenic mechanisms14,16,17. Besides the common inflammatory pathways, RA itself has been considered as an independent risk factor for accelerated CV disease18,19. In a large prospective cohort of women, based on over 100,000 subjects, participants with RA had a significantly increased risk of myocardial infarction compared to those without RA19.

Traditional CV risk factors, including age, hypertension, smoking, and disorders of the lipid profile, all contribute to the propagation of atherosclerosis, and consequently poorer CV outcomes in patients with RA20–22. Yet these traditional Framingham risk factors only partially explain the increased risk for accelerated atherosclerosis in RA. Recent findings support the idea that immune-inflammatory processes associated with RA contribute to the increased risk of ischemic CV disease11,23,24. Inflammatory cytokines that are produced in excess in RA (e.g., tumor necrosis factor-α, platelet-derived growth factor) activate endothelial and subendothelial myofibroblasts that might lead to the accumulation of immunocompetent cells in atherosclerotic plaques1. Classical Framingham as well as other potential risk factors for accelerated atherosclerosis in RA are summarized in Table 15,11.

View this table:
  • View inline
  • View popup
Table 1.

Risk factors for accelerated atherosclerosis in patients with RA.

Mannose-binding lectins (MBL) play an important role in the innate immune system, having the ability to bind to various sugar motifs, and activating the complement system via MBL-associated serine proteases. MBL, as a Toll-like receptor co-receptor, increases microbial uptake as an opsonin, but have the ability to coordinate, amplify, and synchronize innate immune defense mechanisms25. Relatively high amounts of assorted molecular forms of MBL (both homozygous and heterozygous carrier forms) and varying plasma levels of MBL have been described. Polymorphisms in the promoter region of the human MBL2 gene have been shown to give rise to varying plasma levels of MBL26. Among various immune-mediated diseases, MBL polymorphisms have been associated with RA progression; some studies have described an association of MBL polymorphisms with erosive joint destruction, yet other studies could not verify these findings27–29. In a recent study, Jacobsen, et al found that MBL gene polymorphisms were associated with disease activity and physical disability in anti-cyclic citrullinated peptide (CCP)-positive patients with untreated early RA30. The study showed a dose-dependent association between MBL2 expression potential and disease activity as well as physical disability in anti-CCP-positive RA patients before initiation of disease-modifying antirheumatic drug treatment30. Importantly, this study reported that high serum levels of MBL increased the risk of ischemic heart disease in patients with RA.

The followup study of these findings by Troelsen, et al31 is published in this issue of The Journal. The authors describe mortality in a cohort of 229 Danish RA patients and assess whether reported factors and MBL influence risk of overall mortality and mortality due to CV disease. Known predictors of RA mortality were assessed and MBL2 extended genotypes and MBL serum levels were measured. The authors assessed the vital status and causes of death in a relatively long prospective study with a median followup of 10.3 years. At baseline, sex, age, the age at disease onset, presence of erosive arthritis based on hand and feet radiography, assessment of functional ability by Health Assessment Questionnaire (HAQ) score, and the presence of extraarticular manifestations were noted. Additionally, laboratory variables such as IgM rheumatoid factor (RF), serum C-reactive proteins (CRP), and the presence of HLA-DR1 and/or HLA-DR4 were assessed.

Concerning followup data, other known predictive factors, namely smoking, state of nutrition, and comorbidities such as hypertension and diabetes were noted. Although treatment status data for methotrexate (MTX) and anti-TNF inhibitors were retrieved from clinical charts, the use of various glucocorticosteroids, NSAID, acetylsalicylic acid, and statins was not consistently charted. Since these medications have antiinflammatory properties (in addition to anti-atherosclerotic and lipid profile-modifying effects) that can contribute to deceleration of immune-inflammatory properties of atherosclerosis, their intake can fundamentally change the course and outcome of the disease.

Troelsen, et al reported an overall risk of death in RA of 4.0% per year31. Comparing mortality in the RA cohort with mortality in an age- and sex-matched cohort based on the general Danish population, a significantly increased overall mortality rate as well as CV mortality was found, in accord with previous findings4–15. Moreover, multivariate analysis by the authors showed significant predictors of overall death were extraarticular manifestations, positive RF, increased CRP, poor nutritional state, and high serum MBL. Predictors of CV death were HAQ score, increased CRP, poor nutritional state, and high serum MBL levels. Moreover, RA patients with MBL2 genotypes associated with high serum levels of MBL (YA/YA, YA/XA, XA/XA) had excess overall mortality compared to patients with genotypes associated with low serum levels of MBL (YA/YO, XA/YO, YO/YO). The YA/YA genotype was associated with both highest risk of CV death and highest serum levels of MBL. Correspondingly, serum MBL was associated with significantly increased risk of both overall and CV death in RA. A genotype causing high serum MBL might contribute to the perpetuation of both RA severity/mortality and simultaneously accelerated atherosclerosis; therefore, monitoring MBL levels might be useful in diagnosis, CV risk assessment, and followup of RA.

Regarding other predictors of mortality and CV mortality such as disease duration, HAQ score, extraarticular manifestations, positive IgM RF, high CRP, and poor state of nutrition conferred significantly increased risk of overall death, while treatment with MTX and anti-TNF-α drugs contributed to significantly reduced risk of overall death. Both overall and CV mortality were increased in Danish RA patients. In this cohort, states of high MBL production and several previously reported factors contributed significantly to this increased risk of overall death and CV death. In future studies, it would be of interest to assess the objective measures of endothelial dysfunction and atherosclerosis in patients with RA (e.g., flow-mediated vasodilatation, pulse-wave velocity, intima-media thickness, and lipid variables) and correlate them with MBL levels in order to estimate the relationship between these types of lectins and probable CV complications.

This important study points out the key overall and most common CV mortality risk factors in patients with RA. The assessment of specific predictors in patients with RA, including age, sex, disease duration, and genetic factors such as the YA/YA MBL2 genotype (associated with high serum MBL), may aid us in pinpointing high-risk patients, while thorough followup and early cardioprotective, antiplatelet therapy may lead to better clinical outcome for these patients. In addition, adequate treatment of extraarticular manifestations, changes in lifestyle affecting body mass index, reduced cigarette smoking, and proper treatment of comorbidities (e.g., diabetes and hypertension) may all prolong the life expectancy in patients with RA.

REFERENCES

  1. 1.↵
    1. Harris ED,
    2. Budd RC,
    3. Firestein GS,
    4. Genovese MC,
    5. Sergent JS,
    6. Ruddy S,
    7. et al.
    1. Harris ED
    . Clinical features of rheumatoid arthritis. In: Harris ED, Budd RC, Firestein GS, Genovese MC, Sergent JS, Ruddy S, et al., editors. Kelley’s textbook of rheumatology. 7th ed. Philadelphia: Elsevier Saunders; 2005:1243–78.
  2. 2.↵
    1. Turesson C,
    2. O’Fallon WM,
    3. Crowson CS,
    4. Gabriel SE,
    5. Matteson EL
    . Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002;29:62–7.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Van Doornum S,
    2. McColl G,
    3. Wicks IP
    . Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862–73.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Pinals RS
    . Survival in rheumatoid arthritis. Arthritis Rheum 1987;30:473–5.
    OpenUrlPubMed
  5. 5.↵
    1. Vandenbroucke JP,
    2. Hazevoet HM,
    3. Cats A
    . Survival and cause of death in rheumatoid arthritis: a 25-year prospective followup. J Rheumatol 1984;11:158–61.
    OpenUrlPubMed
  6. 6.↵
    1. Reilly PA,
    2. Cosh JA,
    3. Maddison PJ,
    4. Rasker JJ,
    5. Silman AJ
    . Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis 1990;49:363–9.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Naz SM,
    2. Symmons DP
    . Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007;21:871–83.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Symmons DP,
    2. Jones MA,
    3. Scott DL,
    4. Prior P
    . Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998;25:1072–7.
    OpenUrlPubMed
  9. 9.↵
    1. Goodson NJ,
    2. Wiles NJ,
    3. Lunt M,
    4. Barrett EM,
    5. Silman AJ,
    6. Symmons DP
    . Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002;46:2010–9.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Gonzalez-Gay MA,
    2. Gonzalez-Juanatey C,
    3. Martin J
    . Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005;35:8–17.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Szekanecz Z,
    2. Kerekes G,
    3. Dér H,
    4. Sándor Z,
    5. Szabó Z,
    6. Végvári A,
    7. et al.
    Accelerated atherosclerosis in rheumatoid arthritis. Ann NY Acad Sci 2007;1108:349–58.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Wolfe F,
    2. Freundlich B,
    3. Straus WL
    . Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003;30:36–40.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Maradit-Kremers H,
    2. Nicola PJ,
    3. Crowson CS,
    4. Ballman KV,
    5. Gabriel SE
    . Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722–32.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Shoenfeld Y,
    2. Gerli R,
    3. Doria A,
    4. Matsuura E,
    5. Cerinic MM,
    6. Ronda N,
    7. et al.
    Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005;112:3337–47.
    OpenUrlFREE Full Text
  15. 15.↵
    1. Kaplan MJ
    . Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2006;18:289–97.
    OpenUrlPubMed
  16. 16.↵
    1. Snow MH,
    2. Mikuls TR
    . Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheumatol 2005;17:234–41.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Ross R
    . Atherosclerosis — an inflammatory disease. N Engl J Med 1999;340:115–26.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Watson DJ,
    2. Rhodes T,
    3. Guess HA
    . All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003;30:1196–202.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Solomon DH,
    2. Karlson EW,
    3. Rimm EB,
    4. Cannuscio CC,
    5. Mandl LA,
    6. Manson JE,
    7. et al.
    Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303–7.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Chung CP,
    2. Oeser A,
    3. Avalos I,
    4. Gebretsadik T,
    5. Shintani A,
    6. Raggi P,
    7. et al.
    Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006;8:R186.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Solomon DH,
    2. Curhan GC,
    3. Rimm EB,
    4. Cannuscio CC,
    5. Karlson EW
    . Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004;50:3444–9.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Gonzalez-Juanatey C,
    2. Llorca J,
    3. Testa A,
    4. Revuelta J,
    5. Garcia-Porrua C,
    6. Gonzalez-Gay MA
    . Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003;82:407–13.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. del Rincon ID,
    2. Williams K,
    3. Stern MP,
    4. Freeman GL,
    5. Escalante A
    . High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737–45.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Rho YH,
    2. Chung CP,
    3. Oeser A,
    4. Solus J,
    5. Asanuma Y,
    6. Sokka T,
    7. et al.
    Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009;61:1580–5.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Ip WK,
    2. Takahashi K,
    3. Ezekowitz RA,
    4. Stuart LM
    . Mannose-binding lectin and innate immunity. Immunol Rev 2009;230:9–21.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Garred P,
    2. Larsen F,
    3. Madsen HO,
    4. Koch C
    . Mannose-binding lectin deficiency — revisited. Mol Immunol 2003;40:73–84.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Graudal NA,
    2. Madsen HO,
    3. Tarp U,
    4. Svejgaard A,
    5. Jurik G,
    6. Graudal HK,
    7. et al.
    The association of variant mannose-binding lectin genotypes with radiographic outcome in rheumatoid arthritis. Arthritis Rheum 2000;43:515–21.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Jacobsen S,
    2. Madsen HO,
    3. Klarlund M,
    4. Jensen T,
    5. Skjødt H,
    6. Jensen KE,
    7. et al.,
    8. TIRA Group
    . The influence of mannose-binding lectin polymorphisms on disease outcome in patients with early polyarthritis. J Rheumatol 2001;28:935–42.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Barton A,
    2. Platt H,
    3. Salway F,
    4. Symmons D,
    5. Lunt M,
    6. Worthington J,
    7. et al.
    Polymorphisms in the mannose binding lectin (MBL) gene are not associated with radiographic erosions in rheumatoid arthritis or inflammatory polyarthritis. J Rheumatol 2004;31:442–7.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Jacobsen S,
    2. Garred P,
    3. Madsen HO,
    4. Heegaard NH,
    5. Hetland ML,
    6. Stengaard-Pedersen K,
    7. et al.
    Mannose-binding lectin gene polymorphisms are associated with disease activity and physical disability in untreated, anti-cyclic citrullinated peptide-positive patients with early rheumatoid arthritis. J Rheumatol 2009; 36:731–5.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Troelsen LN,
    2. Garred P,
    3. Jacobsen S
    . Mortality and predictors of mortality in rheumatoid arthritis — A role for mannose-binding lectin? J Rheumatol 2010;37:536–43.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 37, Issue 3
1 Mar 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Accelerated Atherosclerosis in Rheumatoid Arthritis: Rationale for Mannose-binding Lectins?
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Accelerated Atherosclerosis in Rheumatoid Arthritis: Rationale for Mannose-binding Lectins?
BRITT NAKKEN, PETER SZODORAY
The Journal of Rheumatology Mar 2010, 37 (3) 482-484; DOI: 10.3899/jrheum.091364

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Accelerated Atherosclerosis in Rheumatoid Arthritis: Rationale for Mannose-binding Lectins?
BRITT NAKKEN, PETER SZODORAY
The Journal of Rheumatology Mar 2010, 37 (3) 482-484; DOI: 10.3899/jrheum.091364
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Celebrating The Journal of Rheumatology’s 50th Year of Publication
  • Cardiovascular Disease Disparities in Systemic Lupus Erythematosus
  • New Advances in the Knowledge of Elemental Enthesis Lesions: Doppler, Erosion, and Thickness
Show more Editorial

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire